Assertio (ASRT) Projected to Post Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT) will likely be issuing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($2.1025) per share and revenue of $8.9660 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

Assertio (NASDAQ:ASRT) last announced its earnings results on Monday, March 16th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.05) by $1.19. The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $6.20 million. Assertio had a negative return on equity of 30.26% and a negative net margin of 25.59%. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Assertio Trading Up 17.4%

NASDAQ ASRT traded up $3.21 on Monday, reaching $21.68. The stock had a trading volume of 1,759,771 shares, compared to its average volume of 141,076. The firm has a market capitalization of $139.84 million, a price-to-earnings ratio of -4.46 and a beta of 0.44. The company has a quick ratio of 1.51, a current ratio of 1.70 and a debt-to-equity ratio of 0.42. Assertio has a 12-month low of $8.61 and a 12-month high of $21.71. The stock has a fifty day moving average price of $15.65 and a two-hundred day moving average price of $12.86.

Hedge Funds Weigh In On Assertio

A number of institutional investors and hedge funds have recently modified their holdings of the company. Rothschild Wealth LLC acquired a new position in shares of Assertio during the fourth quarter worth $172,000. Virtu Financial LLC acquired a new position in Assertio in the third quarter valued at $26,000. Vanguard Group Inc. boosted its stake in Assertio by 0.9% in the third quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock valued at $3,899,000 after acquiring an additional 41,332 shares in the last quarter. Edgewood Management LLC acquired a new position in Assertio in the fourth quarter valued at $975,000. Finally, Perritt Capital Management Inc boosted its stake in Assertio by 51.6% in the third quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock valued at $309,000 after acquiring an additional 119,281 shares in the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.

Wall Street Analyst Weigh In

ASRT has been the topic of a number of research analyst reports. Maxim Group lowered Assertio from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 9th. Wall Street Zen lowered Assertio from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Lake Street Capital lowered Assertio from a “buy” rating to a “hold” rating and cut their price objective for the stock from $45.00 to $18.00 in a research report on Thursday, April 9th. HC Wainwright reaffirmed a “neutral” rating and set a $18.00 price objective (down from $35.00) on shares of Assertio in a research report on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assertio in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $18.00.

About Assertio

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.